权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Combining Irreversible Electroporation with Immunotherapy for the Systemic Treatment of Pancreatic Cancer

不可逆电穿孔与免疫疗法相结合用于胰腺癌的全身治疗

基本信息

批准号：
10154535
负责人：
Rebekah White
金额：
$ 41.97万
依托单位：
UNIVERSITY OF CALIFORNIA, SAN DIEGO
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-01-20 至 2025-12-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10154535
关键词：
Ablation Abscopal effect Adjuvant Adjuvant Therapy Agonist Antibodies Biology CD8-Positive T-Lymphocytes Cells Cellular Assay Cicatrix Clinical Clinical Trials Combined Modality Therapy Contralateral Country DNA delivery Data Dendritic Cells Diagnosis Disease Distant Effector Cell Electroporation Fibrosis Future Goals Human Immune Immune response Immune system Immunity Immunocompetent Immunocompromised Host Immunodeficient Mouse Immunologic Adjuvants Immunotherapeutic agent Immunotherapy Implant Infiltration Inflammation Inflammatory Innate Immune Response Innate Immune System Invaded Laboratories Malignant neoplasm of pancreas Metastatic Neoplasm to the Liver Methods Modeling Mus Neoplasm Metastasis Operative Surgical Procedures Organoids Patient-Focused Outcomes Patients Pre-Clinical Model Proteins RNA Radiation therapy Recurrence Research Specimen T cell response T-Lymphocyte TLR7 gene TNFRSF5 gene Techniques Therapeutic Toll-like receptors Tumor Immunity Tumor-infiltrating immune cells adaptive immune response advanced pancreatic cancer anti-tumor immune response antigen-specific T cells cancer immunotherapy checkpoint inhibition clinical care clinically relevant design immunotherapy clinical trials improved in situ vaccine irradiation mouse model multidisciplinary neoantigens new growth novel pancreatic cancer model pancreatic cancer patients patient derived xenograft model pre-clinical prevent prophylactic reconstitution response subcutaneous treatment response tumor tumor ablation tumor growth tumor microenvironment voltage

项目摘要

Abstract The goal of cancer immunotherapy is to utilize the patient’s immune system to reject the invading “foreign” tumor. However, the pancreatic cancer microenvironment is characterized by an abundance of immunosuppressive cells and a dense stroma that prevents infiltration of anti-tumor immune cells. Electroporation is a technique that has been utilized for decades in the laboratory; electrical voltage is applied to cells to make holes for delivery of DNA and RNA. Irreversible electroporation (IRE) is a technique now being used clinically for ablation of localized tumors that cannot be removed surgically (locally advanced tumors). Our objective is to use IRE as an "in situ vaccine" to help the host recognize foreign tumor proteins (neoantigens) and generate anti-tumor immune responses that will decrease recurrence rates. We have utilized mouse models of pancreatic cancer to show that IRE generates anti-tumor immune cells that prevent growth of new tumors (prophylactic immunity). We hypothesize that combining IRE with agents that augment the immune response will result in inhibition of established, distant tumors (therapeutic immunity or “abscopal” effects). In Aim 1, we will use mouse models to compare the effects of IRE to radiation therapy (XRT), as this is the most relevant clinical comparator. Both methods are used clinically for the ablation (killing) of locally advanced pancreatic cancer but have been shown stimulate systemic immune responses in preclinical models. We hypothesize that IRE will induce stronger immune responses because XRT causes fibrosis (scarring) that will inhibit immune cell infiltration. In Aim 2, we will combine local ablation with local delivery of agents that stimulate the innate immune system in mouse models of metastatic pancreatic cancer. In Aim 3, we will use a novel model in which human tumors and their associated immune cells are implanted into immunocompromised mice in order to create a “humanized” immune system. We will use this model to study the effects of IRE on human tumors. We have assembled a multi-disciplinary team that encompasses broad expertise in IRE, mouse tumor models, stromal biology, immunotherapy, clinical trials, and clinical care of patients with pancreatic cancer. We envision that the combination of IRE with immunotherapy will be first beneficial to patients with locally advanced pancreatic cancer. However, if effective, this approach may also be beneficial to patients with metastatic disease. Since the IRE technique is already in use clinically, a clinical trial in which one or more of the agents to be studied is delivered during or after IRE as adjuvant therapy would likely be feasible in the near future. We will use data from the proposed research to design such a study.

摘要